N-(tert-Butoxycarbonyl)sulfamide | CAS:148017-28-1

We serve N-(tert-Butoxycarbonyl)sulfamide CAS:148017-28-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
N-(tert-Butoxycarbonyl)sulfamide

Chemical Name:N-(tert-Butoxycarbonyl)sulfamide
CAS.NO:148017-28-1
Synonyms:N-(tert-Butoxycarbonyl)sulfamide
tert-Butyl-sulfamoylcarbamat
2-Methyl-2-propanyl sulfamoylcarbamate
tert-Butyl sulfamoylcarbamate
tert-butyl N-sulfamoylcarbamate
Carbamic acid, N-(aminosulfonyl)-, 1,1-dimethylethyl ester
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Molecular Formula C5H12N2O4S
Molecular Weight 196.225
 
Specification:
Appearance:white to light yellow crystal powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Doripenem(CAS:148016-81-3).



Contact us for information like N-(tert-Butoxycarbonyl)sulfamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Carbamic acid, N-(aminosulfonyl)-, 1,1-dimethylethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-Butyl sulfamoylcarbamate Use and application,tert-Butyl sulfamoylcarbamate technical grade,usp/ep/jp grade.


Related News: Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday.4-Fluoro-2-methylbenzaldehyde manufacturer The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.Ethyl 5-bromobenzofuran-2-carboxylate supplier The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.Triphenylamine vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.